Paolo Dellabona

Vita-Salute San Raffaele University — Italy

Immunology and Microbiology · Life Sciences

54h-index11.4kcitations201works5.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune Cell Function and Interaction(107), T-cell and B-cell Immunology(89), Immunotherapy and Immune Responses(63), CAR-T cell therapy research(52), Cancer Immunotherapy and Biomarkers(31)

Publications201 total

Supplementary Tables from Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
2025Open Access
Supplementary Figures from Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
2025Open Access
Supplementary Materials and methods from Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
2025Open Access
The integrative genomic and functional immunological analyses of colorectal cancer initiating cells to modulate stemness properties and the susceptibility to immune responses
Journal of Translational Medicine·2025· 4 citedOpen Access
Human and mouse iNKT cell expansion and engineering with viral vectors
Methods in cell biology·2025
IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity
UNC Libraries·2024Open Access
Author Correction: IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity
UNC Libraries·2024Open Access
CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms
Nature Cancer·2024· 35 citedOpen Access
Supplementary Tables from Pre-existing immunity drives the response to neoadjuvant chemotherapy in esophageal adenocarcinoma
2024Open Access
Supplementary Figures from Pre-existing immunity drives the response to neoadjuvant chemotherapy in esophageal adenocarcinoma
2024Open Access
Supplementary Materials and methods from Pre-existing immunity drives the response to neoadjuvant chemotherapy in esophageal adenocarcinoma
2024Open Access
Supplementary Tables from Pre-existing immunity drives the response to neoadjuvant chemotherapy in esophageal adenocarcinoma
2024Open Access
Data from Pre-existing immunity drives the response to neoadjuvant chemotherapy in esophageal adenocarcinoma
2024Open Access
Supplementary Materials and methods from Pre-existing immunity drives the response to neoadjuvant chemotherapy in esophageal adenocarcinoma
2024Open Access
Supplementary Figures from Pre-existing immunity drives the response to neoadjuvant chemotherapy in esophageal adenocarcinoma
2024Open Access
The longitudinal characterization of immune responses in COVID-19 patients reveals novel prognostic signatures for disease severity, patients’ survival and long COVID
Frontiers in Immunology·2024· 10 citedOpen Access
Genomic binding of NF-Y in mouse and human cells
Genomics·2024· 5 citedOpen Access
Author Correction: IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity
Nature Communications·2024· 1 citedOpen Access
Abstract 3596: Metabolic reprogramming of the tumor microenvironment to enhance the functionality of TCR-edited T cell in colorectal cancer and liver metastases
Cancer Research·2024
IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity
Nature Communications·2024· 53 citedOpen Access
page 1 of 11Next →

Frequent Co-authors

Giulia Casorati(34), Claudia de Lalla(8), Sergio Abrignani(8), Claudio Doglioni(6), Matteo Bellone(6), Elena Tonti(5), Antonio Lanzavecchia(4), Marco Braga(4), Grazia Galli(4), Sandra Nuti(4), C Garavaglia(4), Daniela Montagna(4), Vincenzo Barnaba(3), Valerio Di Carlo(3), Chiara Bonini(3), Federica Cavallo(3), Monica Moro(3), Luca Albarello(3), Lucia Mori(3), Gennaro De Libero(3)